Bruton’s tyrosine kinase inhibitors (BTKi) had a remarkable impact on the treatment of chronic lymphocytic leukemia (CLL), offering a highly efficacious and convenient treatment option. Challenges with toxicity and resistance have led to the development of novel non-covalent BTKi. Tune in to this expert-led TheraTalk, where a panel of nationally renowned CLL experts will discuss considerations for treatment and management of complex patients with relapsed/refractory CLL. Featuring animation to gain a deeper understanding of the pathophysiology of CLL, the role of covalent bonding and differences in novel BTKi mechanisms of action will be included. Don’t miss the opportunity to hear leading strategies for integrating the latest clinical evidence into relapsed/refractory CLL care and have your most pressing questions answered.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/decoding-complex-chronic-lymphocytic-leukemia-cases-expert-theratalk
- Start Date: 2025-01-15 06:00:00
- End Date: 2025-01-15 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - Commercial Support: Source: Lilly (Any division) - Amount: 82500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all